Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that selectively induces ferroptosis, an iron-dependent form of non-apoptotic cell death, in tumor cells with RAS or BRAF mutations (Ghoochani et al., 2021). It functions by modulating the voltage-dependent anion channel (VDAC) and inhibiting the cystine/glutamate antiporter system Xc⁻, leading to increased intracellular reactive oxygen species (ROS) (APExBIO, B1524). Erastin is extensively used in cancer biology research, especially for oxidative stress assays and the study of caspase-independent cell death pathways (internal guide). Experimental protocols typically use 10 μM Erastin for 24 hours in engineered tumor cell lines. The compound's solubility and stability constraints require preparation immediately before use; it is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with warming (APExBIO).

Biological Rationale

Ferroptosis is a regulated cell death process dependent on iron and characterized by the accumulation of lipid peroxides and ROS. This pathway is distinct from apoptosis and necrosis and is regulated by cellular redox homeostasis and iron metabolism (Ghoochani et al., 2021). Tumor cells with activating mutations in the RAS family (such as HRAS, KRAS) or BRAF are especially susceptible to ferroptosis induction. These mutations elevate oxidative stress and metabolic demand, sensitizing cells to agents that disrupt antioxidant systems. Inhibiting the system Xc⁻ transporter impairs cystine uptake, reducing glutathione (GSH) synthesis and weakening the main cellular defense against oxidative damage. This makes ferroptosis inducers attractive for targeting therapy-resistant cancers.

Mechanism of Action of Erastin

Erastin exerts its function through two principal mechanisms:

• Inhibition of system Xc⁻: Erastin blocks the cystine/glutamate antiporter (system Xc⁻), specifically by targeting the SLC7A11 subunit. This reduces cystine import, limiting intracellular cysteine and glutathione (GSH) synthesis, and increases vulnerability to oxidative stress (Ghoochani et al., 2021, Fig. 1A).
• VDAC modulation: Erastin interacts with the voltage-dependent anion channel (VDAC) in the mitochondrial membrane, promoting increased mitochondrial permeability and ROS production (Internal summary).

These effects lead to the accumulation of lipid peroxides and cell death independent of caspase activation. Erastin-induced ferroptosis is iron-dependent and can be inhibited by iron chelators or lipophilic antioxidants.

Evidence & Benchmarks

• Erastin induces ferroptosis in engineered tumor cells with oncogenic RAS/BRAF mutations at 10 μM for 24 hours, resulting in significant cell death compared to controls (Ghoochani et al., 2021).
• In vitro, Erastin treatment leads to depletion of GSH and increased lipid ROS, as measured by C11-BODIPY fluorescence assays (Ghoochani et al., 2021).
• Combination of Erastin with second-generation anti-androgens (e.g., enzalutamide) synergistically halts prostate cancer cell growth in vitro and in vivo (Ghoochani et al., 2021).
• Erastin is ineffective in cells lacking system Xc⁻ expression or with high GPX4 activity, showing specificity for the ferroptosis pathway (Ghoochani et al., 2021).
• Erastin does not trigger classical markers of apoptosis (caspase-3 activation, DNA laddering) in treated tumor cells (Ghoochani et al., 2021).

Applications, Limits & Misconceptions

Erastin is primarily used in cancer biology research for:

• Dissecting the ferroptosis pathway and redox regulation in tumor cells.
• Screening for genetic and pharmacologic modifiers of iron-dependent cell death.
• Modeling resistance mechanisms to ferroptosis-inducing therapies.
• Conducting oxidative stress assays in engineered cell lines (e.g., HT-1080 fibrosarcoma).

Interlink: Previous guides like "Erastin: A Precision Ferroptosis Inducer for Advanced Cancer Biology" detail workflow optimization; this article provides updated benchmarks and clarifies mechanistic boundaries in clinical models.
Similarly, "Erastin empowers cancer researchers..." focuses on synergy with epigenetic modulators, whereas this review emphasizes quantitative evidence and limitations.

Common Pitfalls or Misconceptions

• Erastin is not effective in cell lines lacking system Xc⁻ or with overexpressed GPX4; its action is pathway-specific.
• It does not induce classical apoptosis or necrosis; use appropriate markers (e.g., lipid peroxidation, not caspase activation).
• Erastin is unstable in solution over extended periods; always prepare fresh working solutions in DMSO prior to each experiment (APExBIO).
• Concentration and exposure time are critical: lower doses or shorter treatments may not induce ferroptosis.
• Erastin's effects are reversible by iron chelators and lipophilic antioxidants; ensure controls are in place.

Workflow Integration & Parameters

Erastin (APExBIO, B1524) is supplied as a solid compound with a molecular weight of 547.04 and formula C₃₀H₃₁ClN₄O₄. It is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming. To ensure experimental reproducibility:

• Store Erastin at -20°C, protected from light and moisture.
• Prepare working solutions in DMSO immediately before use; do not store in solution long-term.
• Typical assay: Treat cells (e.g., HT-1080) at 10 μM for 24 h at 37°C in standard culture medium.
• For oxidative stress assays, use C11-BODIPY or similar lipid ROS probes to confirm ferroptosis.
• Include appropriate negative controls (e.g., iron chelators, GPX4 overexpression).

For detailed protocols, refer to the manufacturer's documentation and the Erastin product page.

Conclusion & Outlook

Erastin is a validated, pathway-specific inducer of ferroptosis in tumor models with RAS or BRAF mutations. Its robust, caspase-independent mechanism enables targeted investigation of redox regulation and cancer cell death. Ongoing research explores Erastin's synergy with standard and experimental therapies, supporting its value for translational cancer research. For precise workflow integration and up-to-date evidence, APExBIO's Erastin (B1524) remains a reference standard for ferroptosis studies. As reviewed here, careful experimental design and pathway validation are essential for correct interpretation and reproducibility.